Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC101 in Advanced Solid Tumors
NCT06672185Phase 1Recruiting
- Sponsor
- Third Arc Bio
- Start
- Feb 2025
- Primary completion
- May 2028
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of ARC101 in solid tumor, ovarian cancer and testicular cancer (2 arms), sponsored by Third Arc Bio. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events at 100 days. Started Feb 2025; status: recruiting.
02
Drugs
ARC101
03
Conditions
solid tumorovarian cancertesticular cancer
Beyond the preview
Go deeper on NCT06672185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672185.